People with an inherited condition known as neurofibromatosis type 1, or NF1, often develop non-cancerous, or benign, tumours that grow along nerves. These tumours can sometimes turn into aggressive cancers, but there hasn’t been a good way to determine whether this transformation to cancer has happened.
Researchers from the National Cancer Institute’s (NCI) Center for Cancer Research, part of the National Institutes of Health, and Washington University School of Medicine in St. Louis have developed a blood test that, they believe, could one day offer a highly sensitive and inexpensive approach to detect cancer early in people with NF1.
The blood test could also help doctors monitor how well patients are responding to treatment for their cancer.
The findings are published in the August 31 issue of PLOS Medicine.
NF1 is the most common cancer predisposition syndrome, affecting 1 in 3,000 people worldwide. The condition, caused by a mutation in a gene called NF1, is almost always diagnosed in childhood. Roughly half of the people with NF1 will develop large but benign tumours on nerves, called plexiform neurofibromas.
In up to 15% of people with plexiform neurofibromas, these benign tumours turn into an aggressive form of cancer known as malignant peripheral nerve sheath tumour or MPNST.
Patients with MPNST have a poor prognosis because cancer can quickly spread and often becomes resistant to both chemotherapy and radiation. Among people diagnosed with MPNST, 80% die within five years.
“Imagine going through life with a cancer predisposition syndrome like NF1. It’s kind of like a ticking bomb,” said study co-author Jack F. Shern, M.D., a Lasker Clinical Research Scholar in NCI’s Pediatric Oncology Branch. “The doctors are going to be watching for cancerous tumours, and you’re going to be watching for them, but you really want to discover that transformation to cancer as early as possible.”
However, biopsy findings aren’t always accurate and the procedure can be extremely painful for patients because the tumours grow along nerves. Imaging tests, meanwhile, are expensive and can also be inaccurate.
“What we don’t have right now is a tool to help us determine if within that big, bulky benign plexiform neurofibroma, something bad is cooking and it’s turning into an MPNST,” Dr Shern said. “So we thought, ‘What if we developed a simple blood test where instead of a full-body MRI or a fancy PET scan, we could just draw a tube of blood and say whether or not the patient has an MPNST somewhere?’”
In pursuit of this goal, Dr Shern and study co-leads Aadel A. Chaudhuri, M.D., PhD, and Angela C. Hirbe, M.D., PhD, of Washington University School of Medicine, and their collaborators collected blood samples from 23 people with plexiform neurofibromas, 14 patients with MPNST that had not yet been treated, and 16 healthy people without NF1.
Most of the study participants were adolescents and young adults, the age group in which MPNST most often develops.
The researchers isolated cell-free DNA—that is, DNA shed from cells into the blood—from the blood samples and used whole-genome sequencing technology to look for differences in the genetic material among the three groups.
The cell-free DNA in patients with MPNST had several features that distinguished it from the DNA in the other two groups. For example, patients with MPNST had pieces of cell-free DNA that were shorter than those in people with plexiform neurofibromas or without NF1.
In addition, the proportion of cell-free DNA that comes from tumours—called the “plasma tumour fraction”—in the blood samples was much higher in people with MPNST than in those with plexiform neurofibromas. Together, these differences allowed the researchers to differentiate, with 86% accuracy, between patients with plexiform neurofibromas and those with MPNST.
In the study participants with MPNST, the plasma tumour fraction also aligned with how well they responded to treatment. In other words, if their plasma tumour fraction decreased following treatment, the size and number of their tumours (as measured by imaging scans) also decreased. An increase in plasma tumour fraction was associated with metastatic recurrence.
“You can imagine treating a patient with a chemotherapy regimen. This blood test could easily and rapidly allow us to determine whether the disease is going down or maybe even going away entirely,” Dr. Shern said. “And if you had done surgery and taken out an MPNST, and the blood test was negative, you could use that to monitor the patient going forward to see if the tumour returns.”
Dr Shern noted that one limitation of the current study is its small size, even though it included people with NF1 from two large hospitals. The researchers are planning to conduct a larger trial with more patients. Dr. Shern said the team’s goal is to increase the accuracy of the blood test from 86% to closer to 100%. One approach would be to refine the genetic analysis to focus on genes known to be involved in MPNST.
A simple and inexpensive blood test to detect MPNST early in NF1 patients would be especially useful in developing countries and other resource-poor areas, where access to the equipment and expertise needed to perform imaging is limited, Dr Shern said.
Blood tests of this type also have applications in the early detection and monitoring of patients with other cancer-predisposing genetic disorders, such as multiple endocrine neoplasia, in which benign tumours can turn cancerous, or Li-Fraumeni syndrome, which increases one’s risk for developing several types of cancer.
“This is the perfect opportunity to apply these technologies where we can use a simple blood test to screen an at-risk population,” said Dr Shern. “If the test shows something abnormal, that’s when we know to act and go looking for a tumour.”
The study was supported by the Intramural Research Program of NCI and the National Institute of General Medical Sciences, another part of NIH.